Trial Profile
Phase II study of cisplatin plus S-1 with bevacizumab as first-line therapy for stage III/IV nonsquamous non-small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Apr 2012 New trial record